Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

Dr Scott Tagawa discusses how dose adjustments can optimize the use of enfortumab vedotin in urothelial cancer.

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

which showed that the combination of enfortumab vedotin and pembrolizumab continues to provide superior efficacy compared to chemotherapy in the first-line treatment of patients with locally advanced ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer. Now, new data suggests new ...

Stellar results in a bladder cancer study have prompted Astellas ... Astellas said in a results update this morning that Padcev (enfortumab vedotin) will now bring in JPY 400 to 500 billion ...